You are here

osteoporosis

GlycoNex reports positive results for denosumab biosimilar Phase I trial

Clinical Trials Arena

Tue, 08/20/24 - 10:31 am

clinical trials

In boost to Amgen, analysts predict osteoporosis market share shift

Fierce Pharma

Fri, 06/28/24 - 11:28 am

Amgen’s Prolia Gets FDA Boxed Warning for Risk of Severe Hypocalcemia

Xtalks

Sun, 01/28/24 - 06:28 pm

Amgen faces patent infringement claims on big-selling osteoporosis drug Evenity

Fierce Pharma

Tue, 04/25/23 - 10:10 pm

Sandoz files biosimilar of Amgen osteoporosis drug in US

Pharmaphorum

Tue, 02/7/23 - 12:22 pm

Sandoz reports data from Phase I/III trial of denosumab for osteoporosis

Clinical Trials Arena

Tue, 09/20/22 - 10:07 am

clinical trials

VC firms take osteoporosis drugmaker Radius Health private for almost $900M

Endpoints

Mon, 06/27/22 - 10:04 am

venture capital

Radius falters after a PhIII osteoporosis fail and a breast cancer disappointment, sending shares plummeting

Endpoints

Thu, 12/9/21 - 10:56 am

clinical trials

Bone Health Technologies was recently granted a breakthrough device designation from FDA for its OsteoBoost Vibration Belt, a drug-free alternative for improving bone health and reducing the risk of fracture.

Medical Devices and Diagnostics Industry

Mon, 02/22/21 - 11:48 pm

Bone Health Technologies

OsteoBoost Vibration Belt

Haoma Medica completes first-in-human trial for NaQuinate

Pharmaceutical Business Review

Mon, 11/30/20 - 10:14 am

clinical trials

Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning

Xconomy

Thu, 12/12/19 - 11:02 am

Radius plans to cut loose oncology assets

Fierce Biotech

Wed, 11/6/19 - 10:13 am

endocrine disorders

Merck seeks partner for disease-modifying osteoarthritis drug

PM Live

Wed, 10/9/19 - 11:08 pm

FDA approves Pfenex's osteoporosis therapy

Yahoo/Reuters

Mon, 10/7/19 - 10:56 am

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Pharmaforum

Wed, 08/21/19 - 10:37 am

Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis

Pharmaceutical Business Review

Tue, 07/23/19 - 10:03 am

clinical trials

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Endpoints

Fri, 06/28/19 - 10:04 am

Consumer watchdog petitions FDA for black box warning on Amgen's Prolia

Fierce Pharma

Fri, 04/19/19 - 06:14 pm

spinal fractures

Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost

Endpoints

Tue, 04/16/19 - 09:50 am

FDA approves Evenity for osteoporosis

BioCentury

Tue, 04/9/19 - 07:03 pm

Pages